NCT01021748View on ClinicalTrials.gov

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

November 23, 2009

Primary Completion Date

November 26, 2012

Study Completion Date

July 16, 2014

Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
DRUG

MK-2206

Oral tablets

DRUG

AZD6244

Oral capsules

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY